Verona Pharma plc(VRNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VRNA Verona Pharma plc

Post-Market Trading 06-26 17:30:20 EDT

14.69

-0.35

-2.33%

盘后18.20

+3.51+23.89%

17:30 EDT

High15.58	Low14.60	Vol1.47M
Open15.28	D1 Closing15.04	Amplitude6.52%
Mkt Cap1.19B	Tradable Cap862.84M	Total Shares81.08M
T/O21.96M	T/O Rate2.51%	Tradable Shares58.74M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"VRNA","market":"US","secType":"STK","nameCN":"Verona Pharma plc","latestPrice":14.69,"timestamp":1719432000000,"preClose":15.04,"halted":0,"volume":1473136,"hourTrading":{"tag":"盘后","latestPrice":18.2,"preClose":14.69,"latestTime":"17:30 EDT","volume":29674,"amount":464299.13721,"timestamp":1719437419832},"delay":0,"floatShares":58736251,"shares":81081771,"eps":-0.826283,"marketStatus":"Post-Market Trading","change":-0.35,"latestTime":"06-26 17:30:20 EDT","open":15.28,"high":15.58,"low":14.6,"amount":21959571.367888,"amplitude":0.06516,"askPrice":18.5,"askSize":105,"bidPrice":18,"bidSize":98,"shortable":3,"etf":0,"ttmEps":-0.826283,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1719446400000},"marketStatusCode":4,"adr":1,"adrRate":8,"listingDate":1493265600000,"exchange":"NASDAQ","adjPreClose":15.04,"preHourTrading":{"tag":"盘前","latestPrice":15.35,"preClose":15.04,"latestTime":"09:29 EDT","volume":8033,"amount":124963.33215100001,"timestamp":1719408563625},"postHourTrading":{"tag":"盘后","latestPrice":18.2,"preClose":14.69,"latestTime":"17:30 EDT","volume":29674,"amount":464299.13721,"timestamp":1719437419832},"volumeRatio":0.92966,"impliedVol":1.7583,"impliedVolPercentile":0.9524},"requestUrl":"/m/hq/s/VRNA/wiki","defaultTab":"wiki","newsList":[{"id":"2446734990","title":"Verona Pharma Gets US FDA Approval for Ohtuvayre in Chronic Obstructive Pulmonary Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2446734990","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446734990?lang=en_us&edition=fundamental","pubTime":"2024-06-27 05:25","pubTimestamp":1719437134,"startTime":"0","endTime":"0","summary":"Verona Pharma  said Wednesday that the US Food and Drug Administration has approved Ohtuvayre as maintenance treatment for adult patients with chronic obstructive pulmonary disease.Ohtuvayre is delivered to the lungs through a standard jet nebulizer, the firm said. It expects to launch the inhaled product in Q3.Price: 14.75, Change: +0.06, Percent Change: +0.41","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","VRNA"],"gpt_icon":0},{"id":"2446346512","title":"FDA approves Verona Pharma's therapy for 'smoker's lungs'","url":"https://stock-news.laohu8.com/highlight/detail?id=2446346512","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446346512?lang=en_us&edition=fundamental","pubTime":"2024-06-27 05:00","pubTimestamp":1719435624,"startTime":"0","endTime":"0","summary":"June 26 (Reuters) - The U.S. Food and Drug Administration has given its approval for a treatment from Verona Pharma    for a chronic lung disease that commonly affects smokers, the U.K.-based company ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRNA","REGN","LU0889565916.HKD","LU2023250504.SGD","LU2362541273.HKD","LU0320765992.SGD","LU0109394709.USD","LU0289739699.SGD","BK4588","LU2362540622.SGD","BK4139","LU2362541513.USD","LU0114720955.EUR","BK4007","LU1917777945.USD","LU0053666078.USD","BK4585","LU0882574055.USD","LU2106854487.HKD","LU0058720904.USD","LU1974910355.USD"],"gpt_icon":0},{"id":"2446349110","title":"Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)","url":"https://stock-news.laohu8.com/highlight/detail?id=2446349110","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446349110?lang=en_us&edition=fundamental","pubTime":"2024-06-27 04:57","pubTimestamp":1719435420,"startTime":"0","endTime":"0","summary":"Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients. First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects. LONDON and RALEIGH, N.C., June 26, 2024  -- Verona Pharma plc  , announces the US Food and Drug Administration  approved Ohtuvayre  for the maintenance treatment of chronic obstructive pulmonary disease  in adult patients. Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years.Ohtuvayre is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase 3 and phosphodiesterase 4  that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Ohtuvayre is delivered directly to the lungs through a standard jet nebulizer without the need for high inspiratory flow rates or complex hand-breath coordination.Conference Call Verona Pharma will host an investment community c","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/DlGeVM0kSSxRBZfsvBhMdw--~B/aD01ODE7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/7a37880ab415a7f66acc4aa9a219cd8f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/DlGeVM0kSSxRBZfsvBhMdw--~B/aD01ODE7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/7a37880ab415a7f66acc4aa9a219cd8f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verona-pharma-announces-us-fda-205700549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","VRNA"],"gpt_icon":0},{"id":"2446393430","title":"FDA Decision Day Arrives for Verona's COPD Drug -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2446393430","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446393430?lang=en_us&edition=fundamental","pubTime":"2024-06-26 21:14","pubTimestamp":1719407640,"startTime":"0","endTime":"0","summary":"0914 ET - The FDA's target action date arrives for a decision on Verona Pharma's proposed ensifentrine drug for chronic obstructive pulmonary disease, or COPD. The company says a green light would make ensifentrine the first novel inhaled mechanism for the maintenance treatment of the devastating breathing disorder in more than 20 years. Verona last month inked financing agreements giving it access to up to $650 million ahead of its planned U.S. launch of ensifentrine. According to the American Lung Association, some 11.7 million American adults have COPD, for which there is no cure. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRNA","BK4007"],"gpt_icon":0},{"id":"2445006800","title":"European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2445006800","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2445006800?lang=en_us&edition=fundamental","pubTime":"2024-06-24 23:31","pubTimestamp":1719243099,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were trending higher Monday, rising 0.84% to 1,428.35 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company argenx  and financial services company Banco Bilbao Vizcaya Argentaria , which increased 9.3% and 3.3% respectively. They were followed by biopharmaceutical company Grifols  and pharmaceutical company Sanofi , which were up 2.8% and 3% respectively.The decliners from continental Europe were led by biotech firm Evaxion Biotech  and medical device maker EDAP TMS , which fell 5.7% and 1.3% respectively. They were followed by furniture maker Natuzzi  and telecommunications company VEON , which dropped 0.2% and 1.3% respectively.From the UK and Ireland, the gainers were led by insurance firm Prudential  and biopharmaceutical company Amarin , which increased 7.9% and 7.4% respectively. They were followed by biopharmaceutical company Verona Pharma plc  and tobacco c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765992.SGD","BK4132","BK4107","EVAX","LU0889565916.HKD","BK4117","AKTX","BBVA","BK7062","BK4585","NTZ","BK4207","SNY","BK4588","VRNA","GRFS","BK4082","BK4162","PUK","TRIB","BK4139","ARGX","BDRX","LU0109394709.USD","BK4007","VEON","BK4095","MREO","EDAP","AMRN","AFG","BTI.AU","BTI","BK4505","BK4075"],"gpt_icon":1},{"id":"2445214032","title":"Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2445214032","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2445214032?lang=en_us&edition=fundamental","pubTime":"2024-06-21 00:45","pubTimestamp":1718901904,"startTime":"0","endTime":"0","summary":"Verona Pharma plc's ensifentrine has a PDUFA date on June 26th for COPD treatment, with promising Phase 3 study results suggesting the drug will secure commercial approval.Potential competition from S","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/977459034/image_977459034.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/977459034/image_977459034.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4700200-verona-pharma-next-week-pdufa-date-upside-catalyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4568","LU0889565916.HKD","LU2236285917.USD","LU1829250122.USD","LU1917777945.USD","LU1974910355.USD","LU0320765992.SGD","LU0114720955.EUR","BK4585","LU0058720904.USD","SNY","LU2362541513.USD","BK4532","LU2362541273.HKD","LU0109394709.USD","LU2362540622.SGD","BK4007","LU0053666078.USD","BK4588","VRNA","LU0882574055.USD","LU0289739699.SGD","GSK","GSK.UK","LU2106854487.HKD","REGN","BK4139","LU2023250504.SGD","AZN"],"gpt_icon":0},{"id":"2444469082","title":"European Equities Traded in the US as American Depositary Receipts Move Higher in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2444469082","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444469082?lang=en_us&edition=fundamental","pubTime":"2024-06-20 23:35","pubTimestamp":1718897758,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were trending moderately higher late Thursday morning, rising 0.62% to 1,426.64 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by oil and gas company Eni , which rose 2.4% and then biopharmaceutical firm DBV Technologies , which added 2.1%. They were followed by petroleum refiner Equinor  and electronics company Philips , which were up 1.8% and 1.7%, respectively.The decliners from continental Europe were led by biopharmaceutical companies Cellectis  and Genfit , which fell 2.5% and 2%, respectively. They were followed by biopharmaceutical company Grifols  and medical device maker EDAP TMS , which were down 1.5% and 1.3%, respectively.From the UK and Ireland, the gainers were led by software firm Endava  and biopharmaceutical firm Akari Therapeutics , which climbed 8.1% and 3.9%, respectively. Biopharmaceutical firm NuCana  was up 2.7% and telecommunications operator Vodafone Group  add","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","GNFT","LU0648005311.SGD","BK4505","LU1093756168.USD","DBVT","GRFS","EQNR","LU2092937221.SGD","MREO","LU1093756325.SGD","VOD","GB00BDT5M118.USD","BK4107","BK4201","BK4588","BK4532","BK4139","DAVA","BK4585","CLLS","EDAP","LU0238689110.USD","LU2041044095.USD","BK4011","TRIB","LU1506573853.SGD","E","AKTX","BK4007","BK4132","BK4117","AFG","LU1019632923.USD","LU2463526074.USD","LU1291149836.SGD","LU1019634622.SGD","LU1039938227.USD","BK4134","VRNA","LU0084288595.USD","CRH","NCNA","PHG"],"gpt_icon":0},{"id":"2444290200","title":"Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Nurix Therapeutics (NRIX) and Verona Pharma (VRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2444290200","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444290200?lang=en_us&edition=fundamental","pubTime":"2024-06-20 19:40","pubTimestamp":1718883618,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alkermes (ALKS – Research Report), Nurix Therapeutic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-nurix-therapeutics-nrix-and-verona-pharma-vrna?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-nurix-therapeutics-nrix-and-verona-pharma-vrna?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","VRNA","ALKS","BK4007","BK4139","NRIX","HCSG"],"gpt_icon":0},{"id":"2444328864","title":"European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2444328864","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444328864?lang=en_us&edition=fundamental","pubTime":"2024-06-18 23:18","pubTimestamp":1718723905,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were moving slightly higher late Tuesday morning, rising 0.14% to 1,418.16 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm Evaxion Biotech  was up 11% and biopharmaceutical company Genfit  added 3.4%. They were followed by oil and gas companies TotalEnergies  and Eni , which were both up 1.6%.The decliners from continental Europe were led by semiconductor company Sequans Communications  and telecommunications company VEON , which lost 9.4% and 3%, respectively. Biopharmaceutical company Cellectis  retreated 1.9% and medical device maker EDAP TMS  lost 1.5%.From the UK and Ireland, the gainers were led by cruise line operator Carnival  and utilities company National Grid , which increased 2% and 1.5%, respectively. They were followed by oil and gas company BP  and biopharmaceutical company Akari Therapeutics , which rose 1.1% and 1%, respectively.The decliners from the UK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GNFT","BK4132","BK4107","LU1162221912.USD","SQNS","EVAX","BK4117","AKTX","CLLS","BK4585","BK4532","BK4561","CUK","E","LU1829250122.USD","BK4201","LU2237443382.USD","BK4588","VRNA","LU2237443622.USD","ADAP","TTE","BK4082","BK4141","BK4139","BP","NGG","LU2237443549.SGD","BK4007","LU2237443978.SGD","VEON","BK4208","BK4142","MREO","EDAP","AFG","LU0320765646.SGD","AUTL","BK4505"],"gpt_icon":0},{"id":"2444377064","title":"Verona Pharma plc's (NASDAQ:VRNA) Path To Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2444377064","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444377064?lang=en_us&edition=fundamental","pubTime":"2024-06-18 21:30","pubTimestamp":1718717437,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Verona Pharma plc's...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrna/verona-pharma/news/verona-pharma-plcs-nasdaqvrna-path-to-profitability","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2210149790.SGD","QID","BK4585","NQmain","MNQmain","VRNA","QQQ","BK4007","TQQQ",".IXIC","LU2210150020.SGD","NDAQ","BK4588","QLD","BK4112","SQQQ","LU2095319765.USD","PSQ"],"gpt_icon":0},{"id":"2444619629","title":"Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2444619629","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2444619629?lang=en_us&edition=fundamental","pubTime":"2024-06-17 23:14","pubTimestamp":1718637268,"startTime":"0","endTime":"0","summary":"Bank stocks were helping European equities traded in the US as American depositary receipts nudge marginally higher late Monday morning, rising 0.047% to 1,409.42 on the S&P Europe Select ADR Index. F","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2092937221.SGD","BK4207","ING.AU","MREO","LU1506573853.SGD","BK4139","TRIB","BK4505","BK4551","GB00BDT5M118.USD","LU0889565916.HKD","VRNA","LU1019634622.SGD","CRH","BK4082","LU2041044095.USD","SLN","BK4007","AKTX","EVAX","SAN.AU","DBVT","SNY","LU0320765992.SGD","LU1019632923.USD","CLLS","BK4548","LYG","NCNA","BK7142","LU1093756325.SGD","BK4568","BK4117","LU2463526074.USD","BK4585","LU0109394709.USD","LU0238689110.USD","ASND","ING","LU1039938227.USD","BK4107","BK4011","BNTX","LU1093756168.USD","LU1291149836.SGD","BK7141","SAN","BK4521","AFG","BK7505"],"gpt_icon":0},{"id":"2442566308","title":"European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2442566308","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2442566308?lang=en_us&edition=fundamental","pubTime":"2024-06-12 23:20","pubTimestamp":1718205619,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were moving sharply higher late Wednesday morning, rising 1.59% to 1,445.87 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by software firm SAP  and biopharmaceutical firm Grifols , which rose 3.9% and 3.7%, respectively. Semiconductor company Sequans Communications  and kidney dialysis company Fresenius Medical Care  added 3.2% and 2.8%, respectively.The decliners from continental Europe were led by biopharmaceutical firm Genfit  and pharmaceutical firm Ascendis Pharma , which both retreated 4.7%. Biopharmaceutical company Cellectis  was also down 2.8% and furniture maker Natuzzi  declined 2.2%.From the UK and Ireland, the gainers were led by biotech firm Trinity Biotech  and biopharmaceutical company Mereo BioPharma Group , which climbed 12% and 9.7% respectively. They were followed by biopharmaceutical companies Verona Pharma  and Amarin Corporation , which were up 6.9% and 2.8% resp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4585","BK4532","SAP","AKTX","ASND","BK4023","LU0320765992.SGD","LU0889565916.HKD","BK4196","BK4505","FMS.AU","AUTL","BK4107","GNFT","LU0109394709.USD","SLN","NTZ","BK4141","VOD","SQNS","BK4588","BK4132","AFG","MREO","BK4082","AMRN","CLLS","VRNA","FMS","TRIB","GRFS","BK4007","BK4095","BK7129","BK4117","BK4528"],"gpt_icon":0},{"id":"2442531800","title":"European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2442531800","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2442531800?lang=en_us&edition=fundamental","pubTime":"2024-06-11 23:11","pubTimestamp":1718118680,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were trending sharply lower late Tuesday morning, falling 1.34% to 1,420.05 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by telecommunications company VEON  and pharmaceutical company Ascendis Pharma , which rose 1.4% and 1.1% respectively. They were followed by semiconductor company Sequans Communications  and biotech firm BioNTech , which were up 0.8% and 0.2% respectively.The decliners from continental Europe were led by biotech firm Evaxion Biotech  and biopharmaceutical company Genfit , which fell 6.3% and 5.4% respectively. They were followed by biopharmaceutical company Cellectis  and financial services company Banco Santander , which dropped 2.8% and 2.5% respectively.From the UK and Ireland, the gainers were led by biotech firm Trinity Biotech  and biopharmaceutical company Amarin , which surged 13.5% and 13.3% respectively. They were followed by biopharmaceutical company Aka","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BNTX","LU0889565916.HKD","AUTL","CLLS","AKTX","BK4568","BK4585","EVAX","BK4521","BK4139","ASND","GNFT","LU0320765992.SGD","BHP","BK4141","BHP.AU","BK7142","SQNS","AMRN","BK4548","BDRX","BK7095","BK4117","SAN","VRNA","BK7507","BK4551","BK4007","BK4207","TRIB","BK7511","BK4132","NCNA","BK4535","BK4107","AFG","BK4168","SAN.AU","VEON","LU0109394709.USD","BK4082"],"gpt_icon":1},{"id":"2440494508","title":"European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2440494508","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2440494508?lang=en_us&edition=fundamental","pubTime":"2024-06-03 23:03","pubTimestamp":1717427007,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts fell in Monday trading, declining 0.53% to 1,420.98 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies  and Genfit , which rose 6.9% and 6.8% respectively. They were followed by biopharmaceutical company Grifols  and biotech firm BioNTech , which were up 3.4% and 2.8% respectively.The decliners from continental Europe were led by medical device maker EDAP TMS  and semiconductor company Sequans Communications , which dropped 6.6% and 5.2% respectively. They were followed by biotech firm Evaxion Biotech  and oil and gas company TotalEnergies , which fell 2.7% and 1.9% respectively.From the UK and Ireland, the gainers were led by biopharmaceutical companies Biodexa Pharmaceuticals  and Bicycle Therapeutics , which climbed 8.9% and 6% respectively. They were followed by biotech firm Trinity Biotech  and biopharmaceutical company Verona Pharma , wh","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","DBVT","LU1093756168.USD","CRH","BCYC","BK4011","GB00BDT5M118.USD","GSK.UK","LU2041044095.USD","LU1829250122.USD","ADAP","BNTX","EVAX","BDRX","LU1019634622.SGD","BK4588","TTE","LU2237443382.USD","LU1506573853.SGD","EDAP","LU2463526074.USD","LU1039938227.USD","BK4532","BK4141","AKTX","BK4585","GSK","BK4535","BK4551","LU2237443622.USD","VRNA","AFG","BK4568","LU1019632923.USD","LU1093756325.SGD","BK4117","BK4107","BK4548","TRIB","LU2237443978.SGD","GNFT","BK4139","LU2237443549.SGD","GRFS","LU2092937221.SGD","BK4082","SQNS","BK4201","LU1291149836.SGD","BK4561"],"gpt_icon":0},{"id":"2439916136","title":"European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower","url":"https://stock-news.laohu8.com/highlight/detail?id=2439916136","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2439916136?lang=en_us&edition=fundamental","pubTime":"2024-05-31 23:11","pubTimestamp":1717168297,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts rose Friday morning, gaining 0.61% to 1,418.20 on the S&P Europe Select ADR Index. The index is poised to end the week lower.From con","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","BK4535","LU2041044095.USD","BK4107","BK4011","LU0109394709.USD","LU1019632923.USD","LU2237443382.USD","ASND","AKTX","SQNS","ADAP","LU1039938227.USD","CRH","BK4208","GB00BDT5M118.USD","TRVG","VRNA","BK4007","LU1506573853.SGD","BNTX","BK4139","BK4532","CLLS","GNFT","LU1019634622.SGD","BK4082","BK4551","LU2463526074.USD","LU1093756325.SGD","LU2237443978.SGD","LU0320765992.SGD","BK4568","LU1291149836.SGD","NGG","TTE","BK4585","LU2237443622.USD","NCNA","DBVT","BK4588","BK4548","BK4117","LU1093756168.USD","AFG","BDRX","TRIB","BK4561","LU2237443549.SGD","BK4141"],"gpt_icon":0},{"id":"2439916241","title":"FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD","url":"https://stock-news.laohu8.com/highlight/detail?id=2439916241","media":"Zacks","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2439916241?lang=en_us&edition=fundamental","pubTime":"2024-05-31 21:35","pubTimestamp":1717162500,"startTime":"0","endTime":"0","summary":"Sanofi SNY and Regeneron REGN announced that the FDA extended the review period for a regulatory filing seeking label expansion for their blockbuster drug Dupixent in chronic obstructive pulmonary disease  indication by an additional three months. A final decision is now expected by Sep 27, 2024.The FDA filing seeks approval for Dupixent as an add-on maintenance treatment in certain adult patients with uncontrolled COPD.The delay is on account of the additional data submitted by the companies on the FDA’s request during the ongoing review of Dupixent in COPD. Per the agency, the information submitted by the company constitutes a major amendment to the data filed in its earlier regulatory filing. Management also confirmed that the FDA did not raise any concerns regarding the approvability of the drug in this indication.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-delays-decision-sanofi-sny-133500498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU2023250504.SGD","LU0053666078.USD","LU1974910355.USD","BK4087","BK4585","REGN","LU0109394709.USD","LU0058720904.USD","LU0320765992.SGD","LU0289739699.SGD","SNY","LU0114720955.EUR","LU2106854487.HKD","LU1917777945.USD","BK4588","VRNA","CHMP","LU2362541273.HKD","LU0882574055.USD","LU2362541513.USD","BK4007","LU0889565916.HKD","LU2362540622.SGD"],"gpt_icon":0},{"id":"2438948006","title":"Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2438948006","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2438948006?lang=en_us&edition=fundamental","pubTime":"2024-05-25 22:24","pubTimestamp":1716647043,"startTime":"0","endTime":"0","summary":"Wells Fargo released its annual biopharma M&A screen this week, including weight loss drug developer Viking Therapeutics (VKTX) and gene editing firms CRISPR Therapeutics (CRSP) and Intellia Therapeut","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1097298712/image_1097298712.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1097298712/image_1097298712.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4110471-viking-crispr-cytokinetics-m-a-targets-wells-fargo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ACLX","MRK","PFE","XENE","VKTX","ITCI","BVNKF","ARGX","ABBV","ARDX","AMGN","IBRX","IMVT","NTLA","RVMD","VRNA","APLS","MIRM","MORF","NRIX","HRMY","FOLD","BBIO","APGE","CYTK","XNCR","CGEM","NBIX","BPMC","RCUS","AGIO","ARWR","RNA","DNLI","ALNY","ARVN","MDGL","WFC","BMY","BCYC","EWTX","RYTM","TGTX","CGON","IOVA","BHVN","IDYA","ARQT","DAWN","ZLDPF"],"gpt_icon":1},{"id":"2437320713","title":"Verona Pharma: Key Inflection Point Directly Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2437320713","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437320713?lang=en_us&edition=fundamental","pubTime":"2024-05-24 01:23","pubTimestamp":1716485012,"startTime":"0","endTime":"0","summary":"Verona Pharma plc stock has lost most of its gains from a strong rally late last year.However, the company has a pivotal FDA decision coming up next month around its primary candidate Ensifentrine.Ver","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1836752086/image_1836752086.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1836752086/image_1836752086.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4695314-verona-pharma-key-inflection-point-directly-ahead","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4588","LU0889565916.HKD","LU0882574055.USD","IPXX","LU0058720904.USD","REGN","BK4585","LU0289739699.SGD","BK4139","LU0053666078.USD","LU0320765992.SGD","VRNA","LU0114720955.EUR","BK4007","LU1917777945.USD","SFY","LU2106854487.HKD","LU2023250504.SGD","LU1974910355.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2435710313","title":"Verona Pharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2435710313","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435710313?lang=en_us&edition=fundamental","pubTime":"2024-05-13 23:04","pubTimestamp":1715612640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VRNA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2024 11:04 ET (15:04 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRNA","BK4007"],"gpt_icon":0},{"id":"2434360860","title":"Verona Pharma PLC Reports Q1 2024 Earnings: A Detailed Financial and Strategic Overview","url":"https://stock-news.laohu8.com/highlight/detail?id=2434360860","media":"GuruFocus.com","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434360860?lang=en_us&edition=fundamental","pubTime":"2024-05-11 01:57","pubTimestamp":1715363879,"startTime":"0","endTime":"0","summary":"Net Loss: Reported a net loss of $25.8 million for Q1 2024, compared to a net loss of $16.7 million in Q1 2023, exceeding the estimated net loss of $20.34 million.Revenue: Reported revenue met the analyst estimate of $0.00 million.Earnings Per Share : Reported a loss per share of $0.04, above the estimated EPS of -$0.16.Cash Position: Ended the quarter with $254.9 million in cash and cash equivalents, down from $271.8 million at the end of the previous quarter.R&D Expenses: Research and development expenses decreased to $6.8 million from $12.6 million in Q1 2023, reflecting lower costs post-completion of the Phase 3 ENHANCE program.On May 9, 2024, Verona Pharma PLC  disclosed its financial outcomes for the first quarter ended March 31, 2024, through its 8-K filing. The biopharmaceutical company, which focuses on developing treatments for respiratory diseases, reported a net loss and detailed its strategic preparations for the anticipated U.S. launch of its leading product candidate, En","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verona-pharma-plc-reports-q1-175759773.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VRNA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.veronapharma.com","stockEarnings":[{"period":"1week","weight":-0.0297},{"period":"1month","weight":0.2492},{"period":"3month","weight":-0.0885},{"period":"6month","weight":-0.254},{"period":"1year","weight":-0.2713},{"period":"ytd","weight":-0.2435}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":0.0291},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.1429},{"period":"1year","weight":0.2628},{"period":"ytd","weight":0.1463}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.081831},{"month":2,"riseRate":0.428571,"avgChangeRate":0.024379},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.014175},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.063776},{"month":5,"riseRate":0.5,"avgChangeRate":-0.026344},{"month":6,"riseRate":0.25,"avgChangeRate":-0.031712},{"month":7,"riseRate":0.571429,"avgChangeRate":0.079446},{"month":8,"riseRate":0.428571,"avgChangeRate":0.104858},{"month":9,"riseRate":0.285714,"avgChangeRate":0.001686},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.036203},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.016598},{"month":12,"riseRate":0.714286,"avgChangeRate":0.313093}],"exchange":"NASDAQ","name":"Verona Pharma plc","nameEN":"Verona Pharma plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Verona Pharma plc(VRNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Verona Pharma plc(VRNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Verona Pharma plc,VRNA,Verona Pharma plc股票,Verona Pharma plc股票老虎,Verona Pharma plc股票老虎国际,Verona Pharma plc行情,Verona Pharma plc股票行情,Verona Pharma plc股价,Verona Pharma plc股市,Verona Pharma plc股票价格,Verona Pharma plc股票交易,Verona Pharma plc股票购买,Verona Pharma plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Verona Pharma plc(VRNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Verona Pharma plc(VRNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction